Targeted peptide modification of mesenchymal stem cells enhances their therapeutic efficacy in the treatment of idiopathic pulmonary fibrosis
In this study, we developed a cellular modification strategy based on SA<sub>2</sub>-PEG-Peptides and PEGylation. Co-modifying MSCs with SA<sub>2</sub>-PEG<sub>2000</sub> and SA<sub>2</sub>-PEG<sub>2000</sub>-CAR markedly improved their lung-targeting and retention capacity, resulting in enhanced therapeutic outcomes for IPF. This strategy offers a potential pathway for optimizing MSCs therapies for lung diseases and may be applied to enhance the efficacy of stem cell therapies across a variety of conditions.
Authors
- Wei Cao (ORCID: https://orcid.org/0000-0003-2184-9380)
- Zelin Lei
- Zhao Yan (ORCID: https://orcid.org/0000-0001-9080-5256)
- Rui Jia (ORCID: https://orcid.org/0000-0002-1797-4069)
- Yun Wang (ORCID: https://orcid.org/0000-0003-3661-9959)
- Yang Ren (ORCID: https://orcid.org/0000-0001-9831-6035)
- Xue Bai (ORCID: https://orcid.org/0000-0001-9717-846X)
- Yali Peng
Institutions
- Gansu University of Traditional Chinese Medicine (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/fcell.2025.1710750
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00